Effect of Anatomy of Major Duodenal Papilla on the Difficulty of Cannulation During Endoscopic Retrograde Cholangiopancreatography

December 24, 2019 updated by: Yanglin Pan, Air Force Military Medical University, China

Effect of Anatomy of Major Duodenal Papilla on the Difficulty of Cannulation During Endoscopic Retrograde Cholangiopancreatography (ERCP)

Selective cannulation is an essential step for the success of ERCP. The successful cannulation is influenced by types of disease (such as Sphincter of Oddi Dysfunction and duodenal stricture), the experience of endoscopists and the anatomy of papilla. It is suggested that the size, morphology, orientation and location of major duodenal papilla (MDP), could cause a difficult cannulation (Endoscopy 2016; 48: 657-683). However, the related evidences are limited. The investigators hypothesized that special anatomy of papilla, such as a lanky shape (defined by the higher ratio of length to width) and a deeper location, could increase the difficulty of cannulation. Here the investigators investigated the effects of the anatomy of major duodenal papilla on post-ERCP pancreatitis and the procedure of cannulation in patients undergoing ERCP.

Study Overview

Study Type

Observational

Enrollment (Actual)

658

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Chongqing, China, 400010
        • Department of gastroenterology, Second Affiliated Hospital of Chongqing Medical University
    • Fujian
      • Xiamen, Fujian, China, 361001
        • Department of gastroenterology, Successful Hospital of Xiamen university
    • Henan
      • Kaifeng, Henan, China, 475000
        • Huaihe Hospital of Henan University
    • Shaanxi
      • Xi'an, Shaanxi, China, 710032
        • Endoscopic center, Xijing Hospital of Digestive Diseases

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients with native papilla who underwent ERCP

Description

Inclusion Criteria:

  • age 18-80
  • Patients with native papilla who underwent ERCP

Exclusion Criteria:

  • Prior endoscopic sphincterotomy
  • Minor pancreatic duct as the targeted duct
  • History of prior upper gastrointestinal surgery, such as Billroth I, II and Roux-en-Y
  • Fistula of MDP
  • Papillary carcinoma or adenoma
  • Duodenal obstruction, type II
  • Prior stent placement in common bile duct or pancreatic duct
  • Pregnant or breastfeeding women
  • Unwilling or inability to provide consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
MDP
ERCP was performed by trainees or trainers. Before the cannulation, the photo of major duodenal papilla will be taken carefully to evaluate its size, morphology, orientation and location. All patients initially received wire-guided cannulation with a sphincterotome, If cannulation failed, precut sphincterotomy or the double-wire technique was performed when appropriate. Therapeutic manipulation (eg, sphincterotomy, balloon dilation, stone extraction, and stenting) was done when appropriate. Pancreatic duct stent placement was performed at the discretion of the endoscopists.
evaluate the anatomy of each major duodenal papilla before selective cannulation during ERCP

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
post-ERCP pancreatitis incidence
Time Frame: 48 hours
frequency of post-ERCP pancreatitis
48 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of difficult cannulation
Time Frame: 3 hours
difficult cannulation was defined as when total cannulation time was more than 5minutes, total cannulation attempts more than 5 times or inadvertent pancreatic duct cannulation more than 1 time.
3 hours
Cannulation attempts
Time Frame: 3 hours
the sphincterotome touching the papilla for at least 5 seconds will be considered as one attempt.
3 hours
Total cannulation time
Time Frame: 3 hours
the time from the moment the sphincterotome touch the papilla to the guide wire advance into the target duct.
3 hours
Unintended pancreatic duct cannulation
Time Frame: 3 hours
the guide wire unintentionally entered into the undesired pancreatic duct
3 hours
Complication rate
Time Frame: 48 hours
frequency of any adverse outcome that required hospital admission or prolonged hospital stay necessary for management of the complication, including pancreatitis, bleeding, biliary infection or perforation.
48 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 7, 2018

Primary Completion (Actual)

April 20, 2019

Study Completion (Actual)

April 30, 2019

Study Registration Dates

First Submitted

May 16, 2018

First Submitted That Met QC Criteria

June 7, 2018

First Posted (Actual)

June 8, 2018

Study Record Updates

Last Update Posted (Actual)

December 26, 2019

Last Update Submitted That Met QC Criteria

December 24, 2019

Last Verified

December 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • KY20180081-2

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Endoscopic Retrograde Cholangiopancreatography

Clinical Trials on MDP

Subscribe